Value-Based Cardiology


In this segment, Zachary Bloomgarden, MD; Robert Gabbay, MD, PhD, FACP; Silvio Inzucchi, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, remark on unmet needs in current clinical trial designs for diabetes and heart failure and suggest the potential role, moving forward, of big data analyses.
Michael B. Bottorff, PharmD, discusses the appropriateness for drug monitoring and reversal agents with the use of direct oral anticoagulants.
In this segment, Michael B. Bottorff, PharmD, remarks on the differentiation of direct oral anticoagulants for use in nonvalvular atrial fibrillation.
Michael B. Bottorff, PharmD, of Manchester University, discusses the role of anticoagulants in preventing stroke in patients with nonvalvular atrial fibrillation.
Seth J. Baum, MD; Gary L. Johnson, MD, MBA; Peter Salgo, MD; and Howard Weintraub, MD, consider costs versus value in preventive measures for reducing the risk for cardiovascular events.


July 25-27, 2015
Vancouver, BC, Canada
August 14-16, 2015
Mackinac Island,MI
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST